
Valiant Laboratories Ltd Upgraded to Buy on Strong Financial and Valuation Metrics
2026-11-10 08:52:55Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy as of 9 November 2026. This upgrade follows a comprehensive reassessment of the company’s quality, valuation, financial trend, and technical parameters, reflecting improved fundamentals and an attractive market positioning despite recent price volatility.
Read MoreValiant Laboratories Falls 9.07%: 4 Key Factors Driving the Weekly Decline
2026-11-07 11:02:06Key Events This Week Nov 2: Stock opens at Rs.126.00, down 1.49% amid Sensex gains Nov 3: Technical momentum shifts with mixed indicator signals Nov 4: Very positive quarterly sales reported but profits contract sharply Nov 5: Quality grade upgraded to Hold; valuation shifts to fair Nov 6: Week closes at Rs.116.30, down 1.98% on the day Week OpenRs.126.00</d...
Read More
Valiant Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-11-05 08:03:56Valiant Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive rating to a fair valuation grade. This change reflects a recalibration of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to its historical averages and peer group, signalling a more attractive price point for investors amid a mixed performance backdrop.
Read More
Valiant Laboratories Ltd Quality Grade Upgrade Reflects Mixed Business Fundamentals
2026-11-05 08:00:41Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its quality grade upgraded from below average to average, reflecting notable improvements in its business fundamentals. This upgrade, accompanied by a Mojo Score rise to 67.0 and a Hold rating, highlights a shift in key financial metrics such as return on equity (ROE), return on capital employed (ROCE), and debt management, signalling a more stable operational footing despite recent stock price volatility.
Read More
Valiant Laboratories Ltd Reports Very Positive Quarterly Financial Performance Amid Mixed Market Returns
2026-11-04 11:00:37Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a mixed set of quarterly results for September 2026, reflecting a significant shift in its financial trend from positive to very positive. Despite record quarterly net sales and improved return on capital employed, the company’s profitability metrics have shown notable contraction, prompting a downgrade in its Mojo Grade from Hold to Sell as of 19 August 2026.
Read More
Valiant Laboratories Ltd Shows Bullish Momentum Amid Technical Upgrades
2026-10-29 08:03:10Valiant Laboratories Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by a combination of technical indicators and a robust year-to-date return of 81.16%, significantly outperforming the Sensex’s negative 14.05% over the same period. Investors and analysts are closely monitoring these developments as the stock trades near its 52-week high, signalling renewed optimism in the Pharmaceuticals & Biotechnology sector.
Read More
Valiant Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-10-28 08:05:48Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 1.97%, the stock’s year-to-date return remains robust at 77.66%, significantly outperforming the Sensex’s negative 13.64% over the same period. This article analyses the latest technical indicators, including MACD, RSI, moving averages, and other momentum oscillators, to provide a comprehensive view of the stock’s current market positioning and outlook.
Read More
Valiant Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators
2026-10-26 08:03:02Valiant Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish trend, supported by mixed but increasingly positive signals from key indicators such as MACD, RSI, and moving averages. Despite a modest day decline of 1.97%, the stock’s year-to-date return of 84.88% significantly outpaces the Sensex’s negative 14.19%, highlighting strong underlying strength in this pharmaceuticals and biotechnology micro-cap.
Read More
Valiant Laboratories Ltd is Rated Hold
2026-10-25 10:10:03Valiant Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 October 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.
Read MoreIntimation Of Sad Demise Of The Member Of A Promoter Group Of The Company
15-Nov-2026 | Source : BSEIntimation of sad demise of the member of a Promoter Group of the Company
Announcement under Regulation 30 (LODR)-Newspaper Publication
04-Nov-2026 | Source : BSECopy of Newspaper Publication of Financial Results for quarter and half year ended September 30 2026.
Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Half Year Ended September 30 2026.
02-Nov-2026 | Source : BSEAudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2026.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Valiant Laboratories Ltd has announced 1:4 rights issue, ex-date: 18 Jul 25